A mid-sized pharma company had a therapeutic antibody program which was outside of their indication focus but showed a lot of promise. Therefore, they wanted to find global or territorial partners for further development and commercialization. Initial partnering attempts for this preclinical program had generated just very limited interest.
FHR Consult reviewed the program, IP and competitors. We helped to optimize non-confidential and confidential materials and to organize an electronic data room. FHR Consult also identified additional development work to increase attractiveness of the program. We then contacted new potential partners but also companies that had been approached before.
Significant interest could be generated at new potential partners but also re-contacted companies which led to CDA- and MTA-based discussions with several pharma companies.
Learn more about our services for biotech, pharmaceutical and medtech companies and investors.